Partner Eqyon Healthcare Solutions will market Equazen® products featuring a clinically researched combination of essential fatty acids in pharmacies and parapharmacies.
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is excited to announce that Equazen® products will soon be available in Portugal. The company specializes in clinically researched products in microbiome, cognition, and well-being.
This marks a significant step forward in SFI Health™ EMEA’s ongoing European expansion, following the exclusive license-in agreement signed in February 2024 with Eqyon Healthcare Solutions, a local distributor specialized in healthcare products. Under the terms of the agreement, Eqyon will use its sales and marketing expertise to distribute Equazen® range in pharmacies and parapharmacies.
Equazen® is a trusted global brand offering science-based nutritional solutions to support brain health and cognitive function. Equazen® products feature a unique combination of essential fatty acids (Omega 3 and Omega 6), proven in over 15 clinical studies to support learning, concentration, and healthy brain development.
Matthew Brabazon, GM of SFI Health™ EMEA commented: “We are excited to offer our science-backed Equazen® solutions to Portuguese consumers, who are becoming more proactive in supporting their cognitive needs. Our entry in Portugal is another step of our development plan to grow in the region by widening our partners network and customer base.”
Mr. Nuno Carvalho, CEO of Eqyon, added: “We believe Equazen® products will make a meaningful impact in our market, thanks to their high-quality ingredients and well-documented benefits. We are proud to bring Equazen® back to Portugal and will work closely with SFI Health™ EMEA to strengthen confidence in natural solutions among healthcare professionals and consumers.”
Brain health supplements are one of the fastest growing segments in the global food supplements market: in Europe, between 2023 and 2030, the market is expected to grow at a compound annual rate of 12.5%, driven by increased awareness of cognitive and mental health.
SFI Health™ EMEA and Equazen® are present in several markets, including Spain, United Kingdom, Switzerland, Poland, Czech, Slovak, the Netherlands, the Nordics and the Baltics. The company aims at further widening Equazen® distribution to unlock the potential sales of the brand and make the most of the growing brain health supplements market.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
